Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409342 | 0.86 | MEN1 (0.42) | MEN1KMT2AGAAUSP2SMN1; SMN2 | |
| SCHEMBL408164 | 0.86 | MEN1 (0.42) | MEN1KMT2AGAAUSP2SMN1; SMN2 | |
| SCHEMBL409315 | 0.84 | MEN1 (0.43) | MEN1KMT2AGAAUSP2SMN1; SMN2 | |
| SCHEMBL22000960 | 0.83 | MEN1 (0.40) | MEN1KMT2AGAAUSP2SMN1; SMN2 | |
| SCHEMBL21316726 | 0.79 | MEN1 (0.41) | MEN1KMT2AGAAUSP2SMN1; SMN2 | |
| SCHEMBL23347617 | 0.78 | MEN1 (0.44) | MEN1KMT2AGAAUSP2SMN1; SMN2 | |
| SCHEMBL23347870 | 0.75 | MEN1 (0.44) | MEN1KMT2AGAAUSP2SMN1; SMN2 | |
| SCHEMBL23347864 | 0.75 | MEN1 (0.41) | MEN1KMT2AGAAUSP2SMN1; SMN2 | |
| SCHEMBL20032136 | 0.74 | MEN1 (0.38) | MEN1KMT2AGAAUSP2SMN1; SMN2 | |
| SCHEMBL18993496 | 0.73 | MAPK1 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | MEN1 817/4885KMT2A 2457/4885GAA 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.